Is a copper IUD safe with Wilson disease, or will it raise my copper levels?
Copper IUDs release copper locally and do raise serum copper slightly in healthy women, but current guidelines strongly advise against them in Wilson disease — non-copper IUDs or other contraceptives are recommended instead.
The copper IUD is one of the most effective long-term contraceptives available, but for someone with Wilson disease — a condition defined by the body’s inability to properly excrete copper — this is not just a routine choice. The short answer from published guidelines and specialist consensus is: avoid the copper IUD. The small but real rise in systemic copper it produces is a risk that simply is not worth taking when alternatives exist.1
How much copper does a copper IUD actually release?
This is the key question, and the honest answer is: not very much — in healthy women. The most commonly used device, the Copper T 380A, contains approximately 380 mm² of copper surface area. Studies measuring copper concentrations in uterine and cervical secretions in women using these devices found detectable copper locally, and the copper wire does slowly dissolve over time.2
In women with normal copper metabolism, the copper released by the IUD does produce a small rise in serum copper — but this is partly masked by the fact that serum copper rises naturally with estrogen exposure (including oral contraceptive use), which confounds measurements.3 Most reproductive medicine studies conclude that the systemic copper load from a copper IUD is modest, and in a person with a healthy ATP7B gene it does not reach toxic levels.
The problem is that Wilson disease is specifically a condition where “modest” copper loads cannot be safely handled. The ATP7B transporter — the gene product that is dysfunctional in Wilson disease — is responsible for exporting copper into bile for excretion. Any additional copper absorbed systemically adds to a burden the liver already cannot clear normally.1
What the guidelines say
The 2022 AASLD Practice Guidance on Wilson disease explicitly recommends that patients avoid copper-containing IUDs.1 The EASL guidelines carry the same recommendation.4 Neither guideline frames this as a theoretical concern — it is a practical one grounded in the fundamental pathophysiology of the disease: more copper in means more copper the body must manage, and Wilson disease patients have impaired copper export, not impaired copper import.
The Czlonkowska 2018 review in Nature Reviews Disease Primers similarly notes that copper IUDs should be avoided in Wilson disease, and emphasizes that family planning discussions should be part of routine specialist care for women of reproductive age.5
Does it matter how well my Wilson disease is controlled?
It is tempting to think that if your copper markers are perfectly controlled on treatment, a small additional copper load would not matter. Specialists generally do not accept this reasoning for a few reasons:
- Treatment for Wilson disease reduces copper accumulation but does not “cure” the underlying transport defect. The liver’s capacity to handle excess copper remains impaired.
- Monitoring for the incremental copper contribution of an IUD is not straightforward — serum copper and ceruloplasmin fluctuate for many reasons, and attributing a change specifically to the IUD is difficult in practice.
- Effective non-copper alternatives exist, removing the need to take the risk.
What are the alternatives?
There is good news here: you have multiple effective options, and they work just as well as the copper IUD for contraception.
| Option | Notes for Wilson disease patients |
|---|---|
| Levonorgestrel (hormonal) IUD | Not a copper device — no copper load. Hormone exposure is low and largely local. Discuss with your specialist. |
| Progestin-only pill | No copper. Estrogen-containing pills are generally acceptable in WD but raise serum ceruloplasmin, which complicates copper monitoring. |
| Combined oral contraceptive pill | Can be used; the copper elevation is from estrogen effect on ceruloplasmin synthesis, not actual copper excess. Discuss monitoring implications. |
| Barrier methods | No pharmacological interaction with Wilson disease. |
| Hormonal implant (etonogestrel) | Low-dose progestin, no copper. |
| Permanent sterilization | If appropriate for life stage and family planning goals. |
The hormonal IUD (for example, the levonorgestrel-releasing device) is the most comparable alternative to the copper IUD in terms of long-acting, reversible, highly effective contraception — and it contains no copper. Many specialists and gynecologists working with Wilson disease patients consider it the preferred IUD option.6
A note on estrogen and copper monitoring
If you use any estrogen-containing contraceptive — pill, patch, ring — you will likely see elevated serum ceruloplasmin and serum copper on standard blood tests. This happens because estrogen stimulates ceruloplasmin synthesis in the liver. This is not copper toxicity and does not indicate that your Wilson disease is worsening. However, it does mean that interpreting your routine copper monitoring tests becomes more complicated.1
This is worth flagging to your Wilson disease specialist before starting any estrogen-containing contraceptive. They may want to note the baseline and adjust how they interpret your monitoring labs while you are on it. Free (non-ceruloplasmin-bound) copper is less affected by estrogen and may be more useful for tracking copper control during estrogen use.
Talking to your gynecologist
Many gynecologists — even excellent ones — will not be immediately familiar with Wilson disease contraception guidelines. If you encounter a recommendation for a copper IUD, it is entirely appropriate to say: “I have Wilson disease — a genetic copper metabolism disorder — and my specialist has advised me to avoid copper IUDs because of the risk of copper accumulation.” Then ask about the levonorgestrel IUD or other alternatives.
Bringing a one-page summary of your condition and current treatment to gynecology appointments is genuinely useful. The what to tell your doctor article has a framework for building that kind of portable brief.
If you are actively planning a pregnancy, also review pregnancy and Wilson disease, which covers how treatment is managed during pregnancy and what monitoring looks like in that context.
This article is for patient education, not medical advice. Contraceptive choices in Wilson disease should be made in conversation with both your Wilson disease specialist and your gynecologist, taking your full medical history and current treatment into account.
References
-
Schilsky, Michael L., et al. “A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.” Hepatology 77, no. 4 (2023): 1428–1455. https://doi.org/10.1002/hep.32801. ↩↩↩↩
-
Larsson, Bo, Margareta Frankman, and Lars Hamberger. “Concentrations of Copper in Human Secretions and Weight of the Copper Wire During the 4 to 7 Years After Insertion of a Nova-T IUD.” Fertility and Sterility 36, no. 3 (1981): 399–401. https://doi.org/10.1016/s0015-0282(16)45917-0. ↩
-
Larsson, Bo, and Mats Wennergren. “Investigation of a copper-intrauterine device (Cu-IUD) for possible effect on frequency and healing of pelvic inflammatory disease.” Contraception 15, no. 2 (1977): 143–149. https://doi.org/10.1016/0010-7824(77)90012-9. ↩
-
European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩
-
Czlonkowska, Anna, et al. “Wilson disease.” Nature Reviews Disease Primers 4 (2018): 21. https://doi.org/10.1038/s41572-018-0024-5. ↩
-
Pfeiffenberger, Jan, et al. “Pregnancy in Wilson’s disease: Management and outcome.” Hepatology 67, no. 4 (2018): 1261–1269. https://doi.org/10.1002/hep.29490. ↩
-
Alkhouri, Naim, and Michael L. Schilsky. “Wilson disease: a summary of the updated AASLD Practice Guidance.” Hepatology Communications 7, no. 8 (2023): e0150. https://doi.org/10.1097/HC9.0000000000000150. ↩
-
Rabiee, Atoosa, and Michael L. Schilsky. “Pregnancy in Wilson disease.” Hepatology 67, no. 4 (2018): 1262–1264. https://doi.org/10.1002/hep.29619. ↩
This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.